Fibrobiologics Inc（FBLG）資訊與事件FBLGFibrobiologics Inc

FibroBiologics Secures U.S. Patent No. 12,716,055

FibroBiologics announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,716,055, titled "Treatment of Disc Degenerative Disease and Stimulation of Proteoglycan Synthesis by Fibroblast Conditioned Media and Formulations Thereof." The patent covers methods of promoting disc regeneration by administering fibroblast cells that have been cultured with one or more opioid receptor antagonists and toll-like receptor agonists. These compounds, including opioid receptor antagonists such as naltrexone, stimulate fibroblasts to increase the production of regenerative growth factors, including epidermal growth factor.

FibroBiologics Secures U.S. Patent No. 12,691,147

FibroBiologics announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,691,147, entitled "Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment." The patent describes methods utilizing fibroblasts to improve the engraftment and long-term function of transplanted pancreatic islets, addressing one of the major challenges in islet transplantation.

FibroBiologics Granted European Patent EP 3043825 B1

FibroBiologics announced that the European Patent Office, or EPO, has granted the Company's patent entitled "Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells." The granted patent, European Patent No. EP 3043825 B1, contains 12 claims directed to compositions comprising one or more expression vectors encoding therapeutic polynucleotides, including Sox9, for use in treating individuals in need of cartilage repair. The patent will be validated across selected designated contracting states of the European Patent Convention, extending the Company's protection for this technology into major European markets. Some of the granted claims include: Compositions comprising one or more expression vectors encoding therapeutic polynucleotides that include Sox9, for use in producing chondrocytes or cartilage-type cells in the joint of an individual in need of cartilage repair; Delivery of those expression vectors to fibroblast cells, which then differentiate into chondrocytes or cartilage-type cells, either before or after delivery to the joint; Use of viral and non-viral vectors for genetic modification; Combinations of Sox9 with additional therapeutic genes on a single or multiple vectors.